Merck Sharp & Dohme LLC
Why trials sponsored by Merck Sharp & Dohme LLC stopped, in this sample of ClinicalTrials.gov.
26 stopped trials with a clear reason; 73% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding business | 11 | 42% |
| slow accrual | 5 | 19% |
| safety | 4 | 15% |
| futility | 3 | 12% |
| regulatory | 2 | 8% |
| manufacturing supply | 1 | 4% |
Where it ranks
- #3 of 90 sponsors by share of trials stopped for: safety (15%).
Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.
Trials
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
NCT06829199 · WITHDRAWN · slow accrual
“Since patients were not recruited yet, we would mark this as a Withdrawn status per the NIH definition of that status. Study halted prematurely, prior to enrollment of first participant.” - Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
NCT05226598 · TERMINATED · futility
“MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated.” - A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
NCT04583423 · TERMINATED · funding business
“Business reasons” - Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
NCT04907227 · TERMINATED · futility
“The data did not support study endpoints” - Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)
NCT04425733 · WITHDRAWN · funding business
“Business reasons” - Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
NCT03924869 · TERMINATED · funding business
“Terminated for business reasons” - Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)
NCT03739138 · TERMINATED · funding business
“Business Reasons” - Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
NCT03598608 · TERMINATED · funding business
“Business Reason” - Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)
NCT03295266 · TERMINATED · funding business
“Business and program changes” - A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
NCT02698176 · TERMINATED · funding business
“This study was terminated due to limited efficacy and not due to safety reasons.” - Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
NCT02759315 · TERMINATED · funding business
“The study was terminated based on review of Phase 2 efficacy data” - A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)
NCT01732510 · TERMINATED · funding business
“The study was prematurely stopped due to business reasons.” - A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
NCT01583647 · TERMINATED · safety
“In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs.” - Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
NCT01440595 · TERMINATED · futility
“Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir.” - Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)
NCT01228019 · TERMINATED · safety
“In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs” - A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
NCT01243762 · TERMINATED · funding business
“The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.” - Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors
NCT01190644 · TERMINATED · manufacturing supply
“Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from manufacturer. No alternatives available for use.” - Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)
NCT00771316 · TERMINATED · slow accrual
“feasibility and low enrollment” - Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
NCT00527943 · TERMINATED · safety
“The trial was terminated at the request of the Data and Safety Monitoring Board.” - Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
NCT00521924 · TERMINATED · slow accrual
“Slow Enrollment” - An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)
NCT00430742 · TERMINATED · funding business
“The overall profile does not support development for obesity” - Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)
NCT00358670 · TERMINATED · safety
“Infusion reactions during re-induction cycles after a period of no treatment. Please see "Purpose" section.” - The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)
NCT00441584 · TERMINATED · slow accrual
“Subject accrual was prematurely terminated due slow enrollment.” - Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
NCT00255034 · TERMINATED · slow accrual
“Recruitment targets were unachievable in the currently available population.” - A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)
NCT00140920 · TERMINATED · regulatory
“Recruitment/study discontinued after withdrawal of marketing authorisation. No data entered.” - Remicade® Crohn's Disease Registry Across Canada (Study P02793)
NCT00755937 · TERMINATED · regulatory
“Satisfied a post-marketing commitment to Canadian Health Authorities.”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.